RxDoctor Payments Data

Alfonso Velasco, MD

Family Medicine · Fresno, CANPI 1396740536

Payments from drug & device makers

$926in general payments, 2019–2025

Across 60 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$321
  • Novo Nordisk$191
  • Sanofi-aventis U.S. LLC$114
  • AbbVie$54
  • Mannkind Corporation$50
  • Sanofi Pasteur Inc.$38
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$926 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$30,358
Medicare patients
131
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$53,543
RybelsusSemaglutide15$27,629
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$22,857
EliquisApixaban30$22,650
JanuviaSitagliptin Phosphate13$19,045
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,209
Tresiba Flextouch U-100Insulin Degludec16$17,522
JardianceEmpagliflozin20$16,106
Tresiba Flextouch U-200Insulin Degludec15$13,743
TradjentaLinagliptin12$7,613
Novolog FlexpenInsulin Aspart21$6,723
Atorvastatin Calcium498$6,581
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,483
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,478
Humalog Kwikpen U-100Insulin Lispro11$5,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$191$81,17262 claims
Boehringer IngelheimJardiance, Tradjenta$31$23,71932 claims
PfizerEliquis$14$22,65030 claims
MerckJanuvia$321$19,04513 claims
AbbVieSynthroid$54$1,49418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →